NEW YORK – Janssen Pharmaceutical said on Monday its investigational new drug amivantamab demonstrated activity and was well-tolerated in non-small cell lung cancer patients with EGFR exon 20 insertions in a Phase I trial.
CHRYSALIS is a Phase I, open-label trial evaluating the safety, pharmacokinetics, and efficacy of amivantamab as a monotherapy and in combination with lazertinib, a third-generation EGFR tyrosine kinase inhibitor Janssen is developing with Korean pharmaceutical company Yuhan.